DOI:
10.1055/s-00000172
Transfusionsmedizin
LinksClose Window
References
Zhang C, Wu Z, Li JW. et al.
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.
Int J Antimicrob Agents 2020;
55: 105954
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.